Trial Profile
A Single-arm, Phase II Study of Anlotinib Combined With Platinum/Gemcitabine for First Line Treatment of Advanced Urothelial Carcinoma
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Sep 2021
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Catequentinib (Primary) ; Cisplatin (Primary) ; Gemcitabine (Primary)
- Indications Bladder cancer; Carcinoma; Renal cancer; Ureteral neoplasms; Urethral cancer; Urogenital cancer
- Focus Therapeutic Use
- 07 Sep 2021 New trial record